

The logo for the 2nd Global Liver Health Forum is a stylized, orange-to-red gradient shape resembling a liver. It features a white hexagonal pattern on its surface. The number '2' is large and white, with 'nd' in a smaller font to its upper right. To the right of the '2' is the text 'GLOBAL LIVER HEALTH FORUM' in white, stacked in four lines.

**2nd GLOBAL
LIVER
HEALTH
FORUM**

**SCIENCE TO ADVANCE
LIVER HEALTH**

Friday, 4th June 2021

Virtual Forum

SANOFI 

The logo features a stylized liver shape with a hexagonal pattern, transitioning from orange to red. The text is white and bold.

**2nd GLOBAL
LIVER
HEALTH
FORUM**

SUMMARY



Welcome letter	4
Agenda.....	5

SPEAKER BIOGRAPHIES

Professor Mohammed Eslam.....	6
Professor Leonid Lazebnik	7
Dr Asad Izziddin Dajani	8
Ms Alexandra Fulford	9



WELCOME LETTER

Dear Participant,

It gives me great pleasure to welcome you to our first webinar of the **2nd Global Liver Health Forum!** Following the success of the inaugural Global Liver Health Forum, we aim to continue to raise awareness of the key factors influencing NAFLD - also known as metabolic associated fatty liver disease, or MAFLD - and liver health management and discuss vital paradigm shifts in this field. This year, the Global Liver Health Forum will comprise a series of three webinars, taking place across June and October. We hope this programme will accommodate your busy schedules and ensure you get the most up-to-date information on NAFLD and liver health management throughout the year.

During this first session of the webinar series, we will explore the rationale for a shift from 'NAFLD' towards the terminology of 'MAFLD' and optimal tools for detecting steatosis. The latest evidence for essential phospholipids in the treatment of NAFLD will be discussed, before considering the impact of digital healthcare on disease management.

As we are over 1 year into this life-changing pandemic, we have all become accustomed to virtual meetings. The latest technology ensures the 2nd Global Liver Health Forum will be dynamic, interactive and will allow us to gain perspectives from participants across the world. Throughout the meeting, there will be ample opportunities to engage with the faculty and we encourage you to ask questions in the Q&A sessions.

This event presents an exciting opportunity to collaborate with and learn from world-renowned scientific experts, who will provide new perspectives on this disease and its management. In bringing together this international network of healthcare professionals, the Global Liver Health Forum can facilitate a powerful information exchange that will elevate the quality of patient management. We hope that you and your peers from all over the world will enjoy this engaging and insightful meeting.

We would like to express our sincere gratitude to the people who made this meeting possible. We extend a special thanks to our faculty, who have dedicated their time to sharing their knowledge and passion with us all. We are sure the first webinar of the 2nd Global Liver Health Forum will be an extraordinary meeting.

Yours sincerely,

Etienne Pouteau

Global Head for Digestive Health,
Nutritionals & Claims

Branko Popovic

Global Medical Lead for Digestive Health,
Sanofi Consumer Healthcare

AGENDA



Friday, 4th June 2021

TIME CET (UTC+2)	TOPICS	SPEAKER
10:00–10:05	Welcome and introduction	Sanofi and Dr Asad Dajani (Chair) (UAE)
Session 1		
10:05–10:20	Towards NAFLD to MAFLD – importance of steatosis in the current paradigm shift	Professor Mohammed Eslam (AUS)
10:20–10:35	Detecting steatosis in clinical practice – insights from the EPOCH registry	Professor Leonid Lazebnik (RUS)
10:35–10:45	Q&A	
10:45–10:55	Break	
Session 2		
10:55–11:10	Essential phospholipids – the latest evidence reviewed	Dr Asad Dajani
11:10–11:25	Digital trends in healthcare – the potential impact on NALFD management	Ms Alexandra Fulford (UK)
11:25–11:35	Q&A	
11:35–11:40	Summary and closing remarks	



Professor Mohammed Eslam

Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, Australia.

Professor Eslam is an Associate Professor of hepatology at the Storr Liver Centre, University of Sydney. He heads the fatty liver and genomics groups at Storr Liver Centre and the International Liver Genetics Consortium that led to the identification of genetic and epigenetic factors that impact hepatic steatosis, inflammation and fibrosis. He led the international consensus for redefining fatty liver disease.

Professor Eslam undertakes basic and clinical research on MAFLD, hepatitis C, liver cancer and hepatic fibrosis and is the author of more than 120 publications. He is on the Editorial Board of *Liver International*, *Clinical and Experimental Medicine*, the *Journal of Clinical and Translational Hepatology* and *World Journal of Hepatology*.

Towards NAFLD to MAFLD – importance of steatosis in the current paradigm shift

Presentation overview:

- Key factors to be aware of in the NAFLD/MAFLD paradigm shift
- How 'MAFLD' presents a representative and inclusive diagnosis
- The importance of steatosis in MAFLD diagnosis
- Targeting the metabolic sequelae linked to MAFLD with therapeutics



Professor Leonid Lazebnik

A. I. Evdokimov, Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia. President of the Gastroenterology Scientific Society of Russia.

Professor Lazebnik is a Professor of the Department of Outpatient Internal Medicine at the Moscow State University of Medicine and Dentistry. In addition to his teaching, Professor Lazebnik holds a number of senior roles, including Editor-in-Chief of the *Experimental and Clinical Gastroenterology* journal, President of the Gastroenterological Scientific Society of Russia and Vice-President of the Russian Scientific Society of Internal Medicine.

As a member of the Guidelines Committee of the World Gastroenterology Organization, Professor Lazebnik has played an instrumental role in shaping the way patients are treated and managed.

Detecting steatosis in clinical practice – insights from the EPOCH registry

Presentation overview:

- NAFLD pathology and clinical manifestation
- Steatosis: the clinical implications and current diagnostic methods
- The St-index: a non-invasive screening tool for liver steatosis
- Further insights from the real-world evidence EPOCH study



Dr Asad Izziddin Dajani

Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital, Sharjah, United Arab Emirates.

Dr Dajani is a Consultant Gastroenterologist and Hepatologist at Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital in Sharjah, United Arab Emirates. He was instrumental in establishing the Endoscopy service at the Kuwait and Al Qassimi Hospitals in Sharjah.

Dr Dajani has many publications in the field of his work and is also a member of the editorial board for many reputed journals of gastroenterology and Chairman and Moderator for many of the local Emirates Medical Associations, regional and international symposia and conferences.

Essential phospholipids – the latest evidence reviewed

Presentation overview:

- Recommendations for the initiation of treatment for NAFLD
- Evidence supporting the use of essential phospholipids in patients with NAFLD/MAFLD
- Current data on the safety and tolerability of essential phospholipids



Ms Alexandra Fulford

Kanga Health Ltd.

Ms Fulford is a Senior Strategist and global expert in pharmaceutical social media, with over 15 years' experience in the pharmaceutical industry. She has worked as a Global Lead for a top 10 pharmaceutical company where she developed new global guidelines for social media and emerging digital strategies.

Ms Fulford has a breadth of experience in developing patient-centric, multichannel digital and social media solutions. She also has expertise in developing social media training for corporate clients and affiliates.

Digital trends in healthcare – the potential impact on NALFD management

Presentation overview:

- NAFLD management and follow-up visits for advice and monitoring (lifestyle modification and the required frequency of follow-up visits)
- Digital programmes (for remote guidance on weight loss)
- Mobile applications (behaviour monitoring and education)
- Implementing these tools into clinical practice

**2nd GLOBAL
LIVER
HEALTH
FORUM**

SANOFI 

MAT-GLB-2101368-v1.0
Date of approval: May 2021.